Journal Scans
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986
Efficacy and Safety of Carboplatin-Based Therapy in Advanced Urothelial Cancer
M De Santis, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, I Skoneczna, S Marreaud, R de Wit, R Sylvester
20090828
2009 Sept 28
J Clin Oncol
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986
J Clin Oncol. 2009 Sept 28; Epub ahead of print, M De Santis, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, I Skoneczna, S Marreaud, R de Wit, R Sylvester
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Half of patients with advanced urothelial cancer are unfit to withstand cisplatin-based chemotherapy because of impaired renal function, poor performance status, or comorbidity. Carboplatin-based regimens are less nephrotoxic than cisplatin therapy, but they are slightly less efficacious. Because chemotherapy dosages are derived from studies of fit patients, those who are unfit and older may experience increased toxicity if treated at standard dosing. To date, no regimen specifically tailored for...
